All the latest.
Pattern Awarded $22.5M BARDA Contract to Advance Single-Cell Microbiology System and Critical Care Antimicrobial Susceptibility Testing Panels for Pneumonia and Bacteremia
Austin, TX – November 21, 2024 – Pattern Bioscience, an innovator in rapid diagnosis and antibiotic susceptibility testing for bacterial infections, today announced it has been awarded a cost-share contract worth up to $40.9 million by the Biomedical Advanced Research...
Pattern Bioscience Selected as Winner of ADLM Disruptive Technology Award
AUSTIN, Texas — July 31, 2023 — Pattern Bioscience, Inc., an innovator in rapid diagnosis and antibiotic susceptibility testing (AST) for bacterial infections, today announced that it was named the winner of the Disruptive Technology Award from the Association for...
Pattern Bioscience Secures $28.7 Million in Series C Financing
New funding will be used to accelerate development of first-of-its-kind infectious disease diagnostic platform that will deliver rapid antibiotic treatment guidance AUSTIN, Texas — April 27, 2023 — Pattern Bioscience, Inc., an innovator in rapid diagnosis and...
Pattern Bioscience Appoints Carey-Ann Burnham as Chief Clinical Officer
Renowned microbiologist will bring clinical expertise as the company advances its platform for rapid pathogen identification and antibiotic susceptibility testing AUSTIN, Texas — March 10, 2022 — Pattern Bioscience, Inc., developer of Digital Culture™ technology for...
Pattern Receives FDA “Breakthrough Device Designation” for Pneumonia Action Panel
AUSTIN, Texas, December 8, 2021 – Pattern Bioscience, Inc. has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Pneumonia Action Panel. The test uses Pattern’s Digital CultureTM technology to provide a fast and...
Pattern Raises Additional $9M to Fast-track New Technology for the Fight Against Antibiotic Resistance
Led by Illumina Ventures, the Series B-1 round will accelerate development and validation of transformational bacterial testing technology AUSTIN, Texas, July 14, 2020 – Pattern Bioscience, Inc. today announced $9M in additional funding to accelerate the development...
Pattern Secures $13M in Development Funding
$6.8M CARB-X award plus $6.4M Series B led by Omnimed will help bring new technology to the fight against drug resistance. AUSTIN, Texas, February 4, 2020 – Pattern Bioscience, Inc., formerly operating as Klaris Diagnostics, today announced $13M in funding for the...
Klaris Named Finalist in AMR Diagnostic Challenge
Klaris has been selected as a finalist in the AMR Diagnostics Challenge federal prize competition, and will receive $100,000 to further develop its rapid ID/AST technology. The Challenge is a joint effort between the National Institutes of Health and the HHS Office...
Klaris Diagnostics Secures $3.75 Million to Help Hospitals Fight Superbugs
Series A Financing Led by Omnimed Capital Austin, Texas, May 17, 2018 - Klaris Diagnostics, an in vitro diagnostics company focused on simplifying antibiotic selection for drug-resistant infections, today announced the completion of a $3.75 million Series A...